Tag Archives: Andrew Fein

Analysts Offer Insights on Healthcare Companies: Sunesis Pharma (NASDAQ: SNSS), Sarepta Therapeutics (NASDAQ: SRPT) and Rewalk Robotics (NASDAQ: RWLK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sunesis Pharma (SNSS – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Rewalk Robotics (RWLK – Research Report). Sunesis Pharma (SNSS) In

H.C. Wainwright Remains a Buy on Concert Pharma (CNCE)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Concert Pharma (CNCE – Research Report), with a price target of $29. The company’s shares closed yesterday at $10.35, close to its 52-week low of

Analysts Offer Insights on Healthcare Companies: MEI Pharma (NASDAQ: MEIP) and T2 Biosystems (NASDAQ: TTOO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MEI Pharma (MEIP – Research Report) and T2 Biosystems (TTOO – Research Report) with bullish sentiments. MEI Pharma (MEIP) In a report

H.C. Wainwright Sticks to Its Buy Rating for Constellation Pharmaceuticals Inc (CNST)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Constellation Pharmaceuticals Inc (CNST – Research Report), with a price target of $18. The company’s shares closed yesterday at $8.89. According to TipRanks.com, Fein is

Analysts’ Top Healthcare Picks: BioCryst (BCRX), Crinetics Pharmaceuticals Inc (CRNX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioCryst (BCRX – Research Report), Crinetics Pharmaceuticals Inc (CRNX – Research Report) and Inovio Pharmaceuticals (INO – Research Report) with bullish sentiments.

H.C. Wainwright Reaffirms Their Buy Rating on Unum Therapeutics Inc (UMRX)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Unum Therapeutics Inc (UMRX – Research Report), with a price target of $18. The company’s shares closed yesterday at $3.21, close to its 52-week low